Clinical Trial Update: Addition of Vandetanib to Standard Therapy Pegliposomal Doxorubicin (PLD) [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial evaluating vandetanib in combination with pegylated liposomal doxorubicin for ovarian cancer was terminated, with results posted in 2012.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• Pegylated liposomal doxorubicin (pegylated liposomal doxorubicin)
• Vandetanib (vandetanib)

Snippet

Sponsor: Genzyme, a Sanofi Company | Conditions: Ovarian Cancer | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2012-10-11